Experimental HCV Drugs
Experimental HCV Drugs
EASL Paris: 100% Cure Rate with AL-335, Odalasvir, and Simeprevir for 6 or 8 Weeks
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 28 September 2016 00:00
- Written by Liz HIghleyman
A triple regimen containing 2 experimental hepatitis C drugs -- AL-335 and odalasvir -- plus simeprevir taken for either 6 or 8 weeks cured all previously untreated, non-cirrhotic patients with HCV genotype 1 in a small study, while a dual regimen without simeprevir cured 90%, according to findings presented last week at the EASL special conference New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure in Paris.
Coverage of 21st International AIDS Conference (AIDS 2016)
- Details
- Category: HIV Treatment
- Published on Thursday, 28 July 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 21st International AIDS Conference (AIDS 2016), held July 18-22, in Durban, South Africa.
Conference highlights include PrEP and other biomedical HIV prevention, HIV cure research, experimental antiretroviral therapy, and access to treatment and prevention for key affected populations.
7/28/16
EASL 2016: AbbVie Pangenotypic Combination Achieves High Cure Rate for Genotype 3 Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 22 April 2016 00:00
- Written by Keith Alcorn
A new combination of direct-acting antivirals developed by AbbVie -- ABT493 and ABT-530 -- is highly effective in curing people with genotype 3 hepatitis C virus (HCV) infection and liver cirrhosis, according to results from a pair of Phase 2 studies presented at last week’s EASL International Liver Congress (EASL 2016) in Barcelona.
EASL 2016: ABT-493 + ABT-530 Works Well for Patients Who Did Not Respond to Prior DAAs
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 03 May 2016 00:00
- Written by Michael Carter
An experimental combination of direct acting antivirals (DAAs) from AbbVie is effective and safe in patients with hepatitis C virus (HCV) genotype 1 who did not respond to previous DAA therapy, according to research presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last month in Barcelona. Between 86% and 100% of patients achieved sustained virological response and the combination worked well in the context of pre-existing resistance mutations.
EASL 2016: Vaccines for HIV and Hepatitis C Could Potentially Be Administered Together
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 22 April 2016 00:00
- Written by EASL
Immunization against HIV and hepatitis C virus (HCV) could potentially be combined without compromising immune response to either, though effective vaccines for both diseases are still elusive, according to research presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.
More Articles...
- EASL 2016: Adolescents with Hepatitis C Achieve High Cure Rates with Sofosbuvir/Ledipasvir
- EASL 2016: Novel Therapy RG-101 Plus Antivirals Could Cure Hepatitis C in 4 Weeks
- EASL 2016: $300 Hepatitis C Combination with Ravidasvir to Enter Clinical Trials
- EASL 2016: Sofosbuvir, Velpatasvir, and GS-9857 Works Well for Treatment-Experienced HCV Patients
Web Design and Development by